The randomized, double-blind, placebo-controlled phase 3 trial KEYNOTE-975: Pembrolizumab vs placebo in patients with esophageal carcinoma receiving concurrent definitive chemoradiotherapy

Annals of Oncology(2020)

引用 0|浏览41
暂无评分
关键词
esophageal carcinoma,pembrolizumab,concurrent definitive chemoradiotherapy,double-blind,placebo-controlled
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要